Shares of
Apricus Biosciences IncAPRI plunged more than 50 percent on Monday after the company
disclosed "disappointing" Phase 2b data.
Apricus Biosciences stated that a proof-of-concept study of
fispemifene in men with secondary hypogonadism and sexual dysfunction failed to achieve statistical significance in key clinical benefit endpoints despite an increase in testosterone levels.
Apricus Biosciences continued that its therapy failed to achieve statistical significance for either the erectile function primary endpoint or low libido secondary endpoint. On the other hand, the therapy was generally well-tolerated with no new or significant safety issues arising from the study.
"We are obviously disappointed with these results," said Richard Pascoe, Chief Executive Officer of Apricus. "As a consequence of these results, we will discontinue all development of fispemifene in symptomatic secondary hypogonadism, and focus our resources on our other homegrown pipeline assets. Loading...
Loading...
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
